… We summarize the preclinical and clinical trials, and provide … Therefore, targeting both
OXPHOS and glycolysis is … In summary, targeting immune checkpoints and VEGF/VEGFR is …

… Sorafenib was initially identified as a RAF-1 kinase inhibitor 5… Preclinical studies have shown
that sorafenib inhibits tumor … of multiple signaling pathways including VEGF, PDGF, RAF1…

… as a Raf inhibitor, it later became clear that sorafenib has a … on baseline VEGF levels,
but no predictive value of sorafenib … In preclinical studies, sorafenib demonstrated anti-proliferative …

… inhibition of FGF2 and VEGF-A in preclinical models of head … treatment of sorafenib and
autophagy inhibitors[104], the dual … RAF), which has been established for metastatic colorectal …

… currently in preclinical or clinical development. In the present … Although preclinical studies
demonstrated that Sorafenib … of the tyrosine kinase activity of the VEGF receptor family, but is …

… vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR)… , sorafenib (Nexavar), a
multikinase inhibitor targeting RAF … In summary, our preclinical studies indicated that targeting …

… by RAF mutations and in which selective RAF and MEK … of optimal combinations of sorafenib
(and anti-VEGF/R agents) … , and thus increase the relevance of the preclinical studies (12). …

… RAF, c-Kit, FLT-3 and RET are drug targets of sorafenib in tumor … Patients with elevated
serum VEGF benefit more from sorafenib … In summary, many preclinical and clinical trials have …

… a number of kinase targets including RAF-1, B-RAF, KIT, RET, … VEGF ligand levels. Notably,
CYP3A4, a metabolizing enzyme of regorafenib and sorafenib, was upregulated by both …

… sorafenib is a small molecule tyrosine kinase inhibitor of serine/threonine-protein kinase B-raf
… , is another drug that targets the VEGF pathway by trapping VEGF-A, VEGF-B, and PlGF. …